🚨 Tirzepatide: Real-world Rx beyond #T2D? 🔹 10K+ 🇺🇸 adults used tirzepatide without ⚪️#T2D 🔸 77% 👩, avg BMI 35.8 — >50% had ≥2 obesity-related complications 🔹 At 6 months: – 55% adherence – 91% still on ≤10mg – Slow dose ⤴️ vs trials 👉 Underlines gap between trial

In patients with compensated cirrhosis from metabolic dysfunction–associated steatohepatitis, efruxifermin did not significantly reduce fibrosis at 36 weeks. Full SYMMETRY trial results: nej.md/4kru98f EASLnews | #EASLCongress

"A new study, presented at the European Congress on Obesity in Málaga, Spain, examined data from 2,660 participants in three semaglutide clinical trials in the UK who were living with obesity and/or type 2 diabetes. They found that taking semaglutide enabled them to each work

We’re observing clinically meaningful reductions in micronutrient levels. To date, no high-quality studies have systematically evaluated vitamin and mineral monitoring in patients on next-generation obesity medications. But from the clinic, I can tell you—these insufficiencies

Brillant reflections by Steve Hornby #ASGBI2025

Prof Mysliwiec at #IFSO2025 on cardio-protective effects of metabolic and bariatric surgery (MBS)

Breaking news: Novo Nordisk has announced that chief executive Lars Fruergaard Jørgensen will step down just days after the pioneering maker of obesity drugs cut its profit forecast. on.ft.com/45eRoxD

Bad week at work? Spare a thought for Novo Nordisk's CEO, who thought he was calling into a regular Teams catch-up call -- and was blindsided. Now the guy who oversaw the rise of Ozempic and Wegovy worldwide is on the way out ... bloomberg.com/news/articles/…

An open letter to Novo Nordisk and Lars Jorgensen: open.substack.com/pub/onthepen/p… $nvo $lly

I don’t understand the logic here. GLP-1s consistently deliver inferior outcomes compared to metabolic surgery across key domains: weight, blood pressure, obstructive sleep apnea, type 2 diabetes, and MASLD/MASH. We already have robust outcome data—and in some cases, direct

🚨NEW GLP1 RESEARCH: When GLP-1s stop, the weight comes back—fast. - - - A new Oxford meta-analysis (P04.009, EASO 2025) confirms what many clinicians have observed: stopping GLP-1 receptor agonists often leads to rapid and near-complete weight regain within 1–2 years. 📉 KEY

So proud of you! You’ve worked incredibly hard past year, and it’s been such a joy to watch you grow. Running a marathon after overcoming obesity is no small feat. As your mentor, I couldn’t be prouder. Wishing you all the success and joy as you start next chapter at Mayo Clinic

Why is weight loss surgery called metabolic surgery? Jaime Ponce MD explains it all! ✔️ It regulates hunger and satiety hormones ✔️ Improves blood sugar control ✔️ Reduces risk factors for type 2 diabetes and other metabolic diseases #IFSO #BariatricSurgery #MetabolicSurgery

We’re proud to welcome Dr. Rebecca Puhl as the 2025 Mason Lecturer at #ASMBS2025. A leading voice on weight stigma and health policy, Dr. Puhl brings powerful insight to this year’s meeting. Watch her message and don’t miss her session in DC. ow.ly/umsY50W0VZj

Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results:

This is amazing: the first large, randomized trial to show that exercise improves survival after cancer The benefit from the exercise program was like adding another cancer drug - without the side-effects

This is amazing stuff. In NEJM, an #RCT shows that a structured program of #exercise after surgery and chemo for #ColonCancer can cut the risk of death by 37%. Fabulous news about the value of lifestyle therapy. conscienhealth.org/2025/06/wow-it…

18 months after gastric bypass bariatric surgery: ✴️ BMI from 71 to 40 ✴️ Weight from 456 lbs to 255 lbs

Obesity wisdom from Dr Jason Fung.